S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

BrainsWay Stock Forecast, Price & News

-0.78 (-9.91%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
43,281 shs
Average Volume
25,007 shs
Market Capitalization
$116.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BrainsWay logo

About BrainsWay

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$22.06 million
Book Value
$3.54 per share


Net Income
$-5.39 million
Pretax Margin




Free Float
Market Cap
$116.63 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.90 out of 5 stars

Medical Sector

739th out of 1,388 stocks

Surgical & Medical Instruments Industry

84th out of 126 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

BrainsWay (NASDAQ:BWAY) Frequently Asked Questions

Is BrainsWay a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BrainsWay stock.
View analyst ratings for BrainsWay
or view top-rated stocks.

How has BrainsWay's stock price been impacted by Coronavirus?

BrainsWay's stock was trading at $8.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BWAY shares have decreased by 13.4% and is now trading at $7.09.
View which stocks have been most impacted by COVID-19

Are investors shorting BrainsWay?

BrainsWay saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 68,200 shares, a decrease of 32.9% from the October 31st total of 101,600 shares. Based on an average trading volume of 31,400 shares, the short-interest ratio is presently 2.2 days.
View BrainsWay's Short Interest

When is BrainsWay's next earnings date?

BrainsWay is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for BrainsWay

How were BrainsWay's earnings last quarter?

BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings results on Wednesday, November, 17th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.01. BrainsWay had a negative net margin of 24.34% and a negative trailing twelve-month return on equity of 13.83%. During the same quarter in the previous year, the company earned ($0.04) earnings per share.
View BrainsWay's earnings history

What price target have analysts set for BWAY?

5 Wall Street analysts have issued 1-year price objectives for BrainsWay's shares. Their forecasts range from $12.00 to $17.00. On average, they anticipate BrainsWay's stock price to reach $14.80 in the next twelve months. This suggests a possible upside of 108.7% from the stock's current price.
View analysts' price targets for BrainsWay
or view top-rated stocks among Wall Street analysts.

Who are BrainsWay's key executives?

BrainsWay's management team includes the following people:
  • Christopher R. von Jako, President & Chief Executive Officer
  • Richard Scott Areglado, Chief Financial Officer & Senior Vice President
  • Yiftach Roth, Chief Scientific Officer
  • Aron Tendler, Chief Medical Officer
  • Moria Ankri, Vice President-Research & Development

What other stocks do shareholders of BrainsWay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

When did BrainsWay IPO?

(BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.

What is BrainsWay's stock symbol?

BrainsWay trades on the NASDAQ under the ticker symbol "BWAY."

Who are BrainsWay's major shareholders?

BrainsWay's stock is owned by many different institutional and retail investors. Top institutional investors include Cowen AND Company LLC (8.49%), Wasatch Advisors Inc. (7.10%), Masters Capital Management LLC (5.13%), Phoenix Holdings Ltd. (5.09%), AIGH Capital Management LLC (2.68%) and Morgan Stanley (1.43%).

Which major investors are selling BrainsWay stock?

BWAY stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, and Meitav Dash Investments Ltd..

Which major investors are buying BrainsWay stock?

BWAY stock was acquired by a variety of institutional investors in the last quarter, including Masters Capital Management LLC, Wasatch Advisors Inc., Phoenix Holdings Ltd., Morgan Stanley, Cowen AND Company LLC, and Taylor Frigon Capital Management LLC.

How do I buy shares of BrainsWay?

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BrainsWay's stock price today?

One share of BWAY stock can currently be purchased for approximately $7.09.

How much money does BrainsWay make?

BrainsWay has a market capitalization of $116.63 million and generates $22.06 million in revenue each year. The company earns $-5.39 million in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does BrainsWay have?

BrainsWay employs 100 workers across the globe.

What is BrainsWay's official website?

The official website for BrainsWay is www.brainsway.com.

Where are BrainsWay's headquarters?

How can I contact BrainsWay?

BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at (722) 582-4030 or via email at [email protected].

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.